Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz1. fázis

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

A legfontosabb adatok

Ki végzi
AbbVie
Hol
Boston, Chicago, Cincinnati, Louisville, Philadelphia, Pittsburgh, Portland és Seattle (Egyesült Államok)Mind a 8 helyszín megnézéseMég 9 másik országban, 27 helyszínen
Állapot
Fut, nem toboroz
Fázis
1. fázis
Résztvevők
124 fő, tervezett
Kezdés
2019. jún. 24.
Várható befejezés
2029. márc.
A vizsgálat típusa
Beavatkozással járó, 5 csoport
A vizsgált kezelések
  • Upadacitinib
A regiszteradat frissítve
2026. augusztus 3.

Ki vehet részt

Életkor
2 év – 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 7 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant have total body weight of 10 kg or higher at the time of screening
  • Participant diagnosed with pcJIA (rheumatoid factor-positive or rheumatoid factor-negative polyarticular JIA, extended oligoarticular JIA, or systemic JIA with active arthritis and without active systemic features) with a history of arthritis affecting at least 5 joints within the first 6 months of disease (for extended oligoarticular JIA: <=4 joints within first 6 months of disease and >4 joints thereafter)
  • Participant have 5 or more active joints at the time of screening, defined as the presence of swollen joints (not due to deformity) or, in the absence of swelling, joints with the limitation of movement (LOM) plus pain on motion and/or tenderness with palpitation, with LOM present in at least three of the active joints
  • If receiving methotrexate (MTX), have been taking MTX for at least 12 weeks immediately before and including Study Day 1 on a stable dose of <=20 mg/m2 for at least 8 weeks before and including Study Day 1; in addition, participants should take either folic acid or folinic acid according to local standard of care
  • If on oral glucocorticosteroids, must have been taking oral glucocorticosteroids at a stable dose (no greater than 10 mg/day or 0.2 mg/kg/day, whatever is lower) for at least 1 week before and including Study Day 1

Ki nem vehet részt

  • Participant have prior exposure to JAK inhibitor
  • Participant with diagnosis of enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (JPSA)

Helyszínek itt: Egyesült Államok

Még 9 másik országban, 27 helyszínen

  • Boston Children's HospitalBoston, Egyesült Államok
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, Egyesült Államok
  • Cincinnati Childrens Hospital Medical CenterCincinnati, Egyesült Államok
  • University of LouisvilleLouisville, Egyesült Államok
  • The Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, Egyesült Államok
  • Randall Children's HospitalPortland, Egyesült Államok
  • Seattle Children's HospitalSeattle, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with polyarticular course juvenile idiopathic arthritis. This study consists of three parts: Part 1 is multiple-cohort study that consists of two sequential multiple dose groups. Participants benefiting from the study drug with no ongoing adverse events of special interest or serious adverse events will have option to enroll in Part 2. Part 2 is open-label, long term extension study to evaluate safety and tolerability. Part 3 is an additional safety cohort to evaluate long-term safety and tolerability. Participants <18 years of age who are ongoing in Parts 2 and 3 will participate in an 104 week open-label extension of the study in Part 4.

A vizsgálat 5 csoportja

  • Participants of age group 12 to <18 years receiving dose AA vizsgált kezelés

    Participants of age group 12 to \<18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Kezelés: Upadacitinib

  • Participants of age group 12 to <18 years receiving dose BA vizsgált kezelés

    Participants of age group 12 to \<18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.

    Kezelés: Upadacitinib

  • Participants of age group 6 to <12 years receiving dose AA vizsgált kezelés

    Participants of age group 6 to \<12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Kezelés: Upadacitinib

  • Participants of age group 2 to <6 years receiving dose AA vizsgált kezelés

    Participants of age group 2 to \<6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Kezelés: Upadacitinib

  • Participants of age group 2 to <18 years receiving dose AA vizsgált kezelés

    Participants of age group 2 to \<18 years administered with upadacitinib dose A as described in the protocol.

    Kezelés: Upadacitinib

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
A regiszteradat frissítve
2026. augusztus 3.